The startup's technology uses a droplet microfluidics approach for cell isolation and phenotypic detection, and is being targeted for use by hospitals.
The financing will go toward further development of Klaris' phenotypic single-cell technology that can rapidly identify pathogens and determine their response to antibiotics.
